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Abstract: Human campylobacteriosis represents an infectious enteritis syndrome caused by Campy-
lobacter species, mostly Campylobacter jejuni. Given that C. jejuni infections are rising worldwide
and antibiotic treatment is usually not indicated, novel treatment options for campylobacteriosis
are needed. Urolithin-A constitutes a metabolite produced by the human gut microbiota from
ellagitannins and ellagic acids in berries and nuts which have been known for their health-beneficial
including anti-inflammatory effects since centuries. Therefore, we investigated potential pathogen-
lowering and immunomodulatory effects following oral application of synthetic urolithin-A during
acute campylobacteriosis applying perorally C. jejuni infected, microbiota-depleted IL-10−/− mice as
preclinical inflammation model. On day 6 post infection, urolithin-A treated mice harbored slightly
lower pathogen loads in their ileum, but not colon as compared to placebo counterparts. Importantly,
urolithin-A treatment resulted in an improved clinical outcome and less pronounced macroscopic and
microscopic inflammatory sequelae of infection that were paralleled by less pronounced intestinal
pro-inflammatory immune responses which could even be observed systemically. In conclusion, this
preclinical murine intervention study provides first evidence that oral urolithin-A application is a
promising treatment option for acute C. jejuni infection and paves the way for future clinical studies
in human campylobacteriosis.
Keywords: Urolithin-A; enteropathogenic infection; Campylobacter jejuni; immune-modulatory effects;
secondary abiotic IL-10−/− mice; campylobacteriosis model; host-pathogen interaction; preclinical
intervention study; ellagitannins; lipooligosaccharide
1. Introduction
Campylobacteriosis is clinically characterized by acute enteritis upon infection with
thermo-tolerant Campylobacter species, in most cases Campylobacter jejuni [1–6]. In particular,
the global increase in poultry consumption drives a tremendous rise in human C. jejuni infec-
tions making campylobacteriosis a serious health problem and economic burden [3,5]. Given
that the avian intestinal tract represents the major pathogen reservoir, the symptom-free
colonization of livestock such as chickens and turkeys and the subsequent contamination of
the meat products during the slaughter process may mount in acute disease and potential
post-infectious sequelae in the infected human consumers [3–5]. The absence of clinical
signs in the Campylobacter colonized avian host has been attributed to a non-responsiveness
of the birds’ innate immune system to the bacteria. This is in support of the resistance of
birds to lipopolysaccharide (LPS) within the cell walls of Gram-negative bacteria including
pathogens of the Campylobacter clade which produce a truncated variant of LPS termed
lipooligosaccharide (LOS) [7]. Results from previous studies suggest that these differences
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in pathogen recognition might be caused by species-specific variations in the recognition
of Campylobacter LOS by the specific innate receptor Toll-like-receptor (TLR)-4 [8].
After peroral ingestion, the spiral-shaped motile bacteria multiply in the intestinal
lumen of the human host and target enterocytes. Non-flagellated immobile mutants of
the pathogen are apathogenic [4,6]. Furthermore, disease induction by C. jejuni depends
on adhesion of the pathogen to intestinal cells as well as active invasion of enterocytes.
In contrast to birds, humans are highly sensitive to LPS/LOS [9] and the human innate
immune system, established in the subepithelial tissues, is activated by invading C. je-
juni. Pathogenic LOS has been shown to be a major virulence factor triggering human
campylobacteriosis characterized by bloody diarrhea [10], which may ultimately result
in sepsis, particularly in immunocompromised individuals [6]. In turn, innate immune
cells such as dendritic cells, neutrophils, macrophages and monocytes are recruited to
the infected intestines [4] and produce reactive oxygen species (ROS) thereby promoting
intestinal tissue destruction and apoptosis, both histopathologic hallmarks of acute campy-
lobacteriosis [1,2,10]. The essential role of C. jejuni-LOS in human campylobacteriosis is
further underlined by post-infectious sequelae such as Guillain–Barré syndrome or reactive
arthritis which have been shown to be significantly associated with sialylated LOS of the
infecting C. jejuni strain, and additionally with the severity of the preceding gastrointestinal
disease [11]. The role of C. jejuni-LOS as a master regulator during human campylobac-
teriosis was finally confirmed at the molecular level, indicating that LOS induced innate
immune activation triggers apoptosis and sodium malabsorption [10]. In consequence,
LOS induced innate immune responses provide a useful target for the development of
novel pharmaceutical intervention strategies in order to dampen C. jejuni induced im-
munopathogenesis. However, this necessitates the development of convenient and reliable
experimental in vivo infection and inflammation models which has been complicated by
the effective physiological colonization resistance of conventional laboratory mice against
C. jejuni [12] and furthermore, by the approximately 10,000-fold less responsiveness of
mice to LOS when compared to humans [13]. These limitations were solved by generat-
ing microbiota-depleted mice following antibiotic treatment which are sensitized to LOS
by deficiencies in genes for interleukin (IL) 10 or single-Ig-interleukin-1 related receptor
(SIGIRR) [7,14,15]. Upon C. jejuni infection, these mice develop severe intestinal inflamma-
tion and clinical signs of human campylobacteriosis, which also holds true for intestinal
histopathological changes characterized by innate immune cell accumulation, apoptosis
and tissue destruction within the infected intestines [2,16–18]. The role of LOS in campy-
lobacteriosis was finally confirmed by the amelioration of C. jejuni induced enterocolitis
in mice lacking TLR4 [7]. Given that microbiota-depleted and LOS sensitized IL-10−/−
mice did not develop campylobacteriosis upon infection with non-motile, flagella-deficient
C. jejuni mutants [19], these mice were further used as a convenient model for studying
C. jejuni virulence factors triggering acute campylobacteriosis [7], including proteases such
as PepP [20] and HtrA [21,22]. This campylobacteriosis model was further successfully
used to evaluate disease-alleviating properties of distinct molecules such as vitamin C [23],
vitamin D [24], carvacrol [25], and the neuropeptides PACAP [26] and NAP [27] in acute
C. jejuni induced enterocolitis [7].
To provide novel treatment options for campylobacteriosis in a preclinical setting,
we further searched for a pharmaceutically well-documented non-toxic molecule, which
combines potent anti-inflammatory and anti-oxidant effects with rather low anti-microbial
activities to avoid the emergence of pathogenic resistance and intestinal dysbiosis. In fact,
urolithin-A constitutes a promising candidate fulfilling all these prerequisites. The molecule
is produced by the human gut microbiota from dietary plant-derived ellagitannins and
ellagic acid present in berries, pomegranate, and nuts, which have been known for their
anti-inflammatory effects since centuries [28–31]. Treatment studies revealed that urolithin-
A and its precursors ameliorate chemically induced colitis in rodents [32] and protect
humans from both acute and chronic inflammatory diseases [33]. Modes of action by
urolithin-A include direct oxygen radical scavenging properties [34]. It further dampens
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LPS/LOS induced innate immune responses [31,35–37] and ROS production by inhibition
of myeloperoxidases (MPO) / lactoperoxidases (LPO) and the nuclear-factor-kappa-B
(NFκB) subunit translocation to the nucleus even at low concentrations [38].
Therefore, these scientifically confirmed health-beneficial effects prompted us to
evaluate urolithin-A as a potential novel treatment option for acute campylobacteriosis
in C. jejuni infected microbiota-depleted IL-10−/− mice. The major aim of our study was
to test whether synthetic urolithin-A applied via the oral route in drinking water at low
concentrations (in the µM range) ameliorates pathogen-induced intestinal and systemic
inflammation.
2. Results
2.1. Gastrointestinal Pathogen Loads following Urolithin-A Treatment of C. jejuni Infected
IL-10−/− Mice
Microbiota depleted IL-10−/− mice were perorally infected with 109 colony forming
units (CFU) C. jejuni strain 81-176 on days 0 and 1 and subjected to either urolithin-A or
placebo treatment via the drinking water as initiated on day 2 p.i. Our cultural analyses
revealed that on days 2, 3 and 4 post infection (p.i.), fecal C. jejuni numbers were lower
in the urolithin-A as compared to the placebo cohort (p < 0.01–0.001), whereas later-on,
comparably high median pathogen loads of approximately 109 CFU per g fecal sample
could be determined (not significant (n.s.); Supplementary Figure S1). On day 6 p.i., we
assessed the pathogen burdens in defined compartments within the gastrointestinal tract
and found comparable luminal C. jejuni cell numbers in the stomach, duodenum and colon
of urolithin-A and placebo treated mice (n.s.; Figure 1). In the ileum, however, median
C. jejuni loads were almost two log orders of magnitude lower in the former versus the latter
(p < 0.05; Figure 1). Of note, two and three mice from the urolithin-A cohort had expelled
the C. jejuni bacteria from the ileal and duodenal lumen until day 6 p.i., respectively,
whereas all placebo counterparts were C. jejuni culture-positive (Figure 1). Hence, ileal
pathogen burdens were lower following urolithin-A versus placebo application to C. jejuni
infected IL-10−/− mice.
Figure 1. Gastrointestinal pathogen numbers upon urolithin-A treatment of C. jejuni infected IL10−/−
mice. On day (0) and d1, microbiota depleted IL-10−/− mice were orally infected with C. jejuni
strain 81-176 and treated with urolithin-A (URO, open circles) or placebo (PLC, closed circles)
via the drinking water starting on d2 post infection. On d6, the gastrointestinal pathogen loads
were determined by culture (expressed as colony forming units per g luminal content, CFU/g).
Medians (black bars), significance levels (p values) determined by the Mann–Whitney U test and total
numbers of included animals (in parentheses) are given. Data were pooled from three independent
experiments.
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2.2. Clinical Outcome Upon Urolithin-A Treatment of C. jejuni Infected IL-10−/− Mice
Next, we surveyed the clinical course in C. jejuni infected mice during urolithin-A treat-
ment. When applying clinical scores for typical clinical signs of acute campylobacteriosis
including wasting and bloody diarrhea, mice from the urolithin-A cohort displayed lower
clinical scores as compared to placebo counterparts as early as day 2 p.i. (p < 0.01–0.001;
Supplementary Figure S2). At the end of the observation period on day 6 p.i., when placebo
mice suffered from severe C. jejuni induced disease, urolithin-A treated animals exhibited
less pronounced clinical signs (p < 0.01–0.001; Figure 2). Notably, 35.7% of mice from the
urolithin-A cohort were clinically uncompromised and were lacking any signs of disease
(Figure 2). Hence, urolithin-A treatment led to a better clinical outcome in C. jejuni infected
IL-10−/− mice.
Figure 2. Clinical outcome upon urolithin-A application to C. jejuni infected IL-10−/− mice. Follow-
ing C. jejuni strain 81-176 infection on days 0 and 1, microbiota depleted IL-10−/− mice were treated
with urolithin-A (URO, open circles) or placebo (PLC, closed circles) via the drinking water starting
on d2 post infection. Prior and at distinct time points post infection, the (A) overall clinical outcome
was quantified in each mouse by standardized clinical scores assessing in particular (B) wasting,
(C) stool consistency (diarrhea) and (D) fecal blood. Naive mice were used as negative controls
(open diamonds). Medians (black bars), significance levels (p values) calculated by the ANOVA test
with Tukey post-correction or by the Kruskal–Wallis test and Dunn’s post-correction and the total
numbers of included animals (in parentheses) are given. Data were pooled from three independent
experiments.
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2.3. Macroscopic and Microscopic Inflammatory Outcomes Upon Urolithin-A Treatment of
C. jejuni Infected IL-10−/− Mice
Since significant shrinkage of the affected intestine can be observed during intestinal
inflammation [39], we measured the large intestinal lengths of each mouse after sacrifice.
On day 6 p.i., mice from both the urolithin-A and placebo groups displayed shorter colons
when compared to naive animals (p < 0.001), but with longer colonic lengths measured in
the former as compared to the latter (p < 0.05; Figure 3A), indicative of less pronounced
gross C. jejuni induced large intestinal inflammation upon urolithin-A treatment. We further
quantified the severity of colonic inflammation microscopically by histopathology scoring
of hematoxylin and eosin stained colonic paraffin sections. C. jejuni infection of mice from
the placebo cohort resulted in severe histopathological changes observed in colonic tissue
samples (p < 0.001 versus naive), which were, however, less pronounced in urolithin-A
versus placebo treated mice on day 6 p.i. (p < 0.05; Figure 3B). We additionally assessed
pathogen-induced apoptotic responses in colonic epithelial cells after immunohistochemical
staining of colonic samples. C. jejuni infection resulted in increased apoptotic epithelial
cell counts (p < 0.01–0.001), but with lower numbers in urolithin-A as compared to placebo
treated mice on day 6 p.i. (p < 0.001; Figure 3C). Hence, urolithin-A treatment of IL-
10−/− mice resulted in less pronounced macroscopic as well as microscopic inflammatory
responses following C. jejuni infection.
Figure 3. Macroscopic and microscopic inflammatory outcomes upon urolithin-A application to
C. jejuni infected IL-10−/− mice. Following C. jejuni strain 81-176 infection on days 0 and 1, microbiota
depleted IL-10−/− mice were treated with urolithin-A (URO, open circles) or placebo (PLC, closed
circles) via the drinking water starting on d2 post infection. On d6, (A) the colonic lengths were
measured and (B) the histopathological changes in large intestinal ex vivo biopsies quantified using
standardized histopathology scores. (C) Furthermore, the average numbers of apoptotic colonic
epithelial cells (positive for cleaved caspase3, Casp3+) were determined microscopically from six high
power fields (HPF, 400 × magnification) per mouse applying in situ immunohistochemical analysis
of large intestinal paraffin sections. Naive mice were used as negative controls (open diamonds).
Medians (black bars), significance levels (p values) calculated by the ANOVA test with Tukey post-
correction or by the Kruskal–Wallis test and Dunn’s post-correction and the total numbers of included
animals (in parentheses) are given. Data were pooled from three independent experiments.
2.4. Colonic Pro-Inflammatory Immune Responses Upon Urolithin-A Treatment of C. jejuni
Infected IL-10−/− Mice
In order to dissect potential immunomodulatory properties of urolithin-A in C. jejuni
infected mice in more detail, we quantified distinct immune cell populations in the colonic
mucosa and lamina propria applying in situ immunohistochemistry. On day 6 p.i., colonic
numbers of macrophages and monocytes and of T lymphocytes were lower in urolithin-A
versus placebo treated mice (p < 0.01 and p < 0.001, respectively; Figure 4A,B), whereas C. je-
juni induced increases in regulatory T cells and B lymphocytes within the large intestines
were comparable in both treatment cohorts (p < 0.001 versus naive; Figure 4C,D).
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Figure 4. Colonic immune cell responses upon urolithin-A application to C. jejuni infected IL-10−/−
mice. Following C. jejuni strain 81-176 infection on days 0 and 1, microbiota depleted IL-10−/− mice
were treated with urolithin-A (URO, open circles) or placebo (PLC, closed circles) via the drinking
water starting on d2 post infection. On d6, the average numbers of (A) F4/80+ macrophages and
monocytes) (B) CD3+ T lymphocytes), (C) FOXP3+ regulatory T cells and (D) B220+ B lymphocytes
were determined microscopically from six high power fields (HPF, 400 × magnification) per animal in
immunohistochemically stained large intestinal paraffin sections. Naive mice were used as negative
controls (open diamonds). Medians (black bars), significance levels (p values) calculated by the
ANOVA test with Tukey post-correction or by the Kruskal–Wallis test and Dunn’s post-correction
and the total numbers of included animals (in parentheses) are given. Data were pooled from three
independent experiments.
We further assessed intestinal pro-inflammatory mediator secretion and determined
lower interferon-γ (IFN-γ) concentration in both colonic and ileal explants taken from
urolithin-A versus placebo treated mice on day 6 p.i. (p < 0.05 and p < 0.001, respectively;
Figure 5A,B) which also held true for ileal tumor necrosis factor-α (TNF-α) protein levels
(p < 0.05; Figure 5C). Furthermore, increased monocyte chemoattractant protein-1 (MCP-1)
and nitric oxide concentrations were assessed in the ileum of placebo, but not urolithin-A
treated C. jejuni infected mice (p < 0.05 and p < 0.001, respectively; Figure 5D,E). Hence,
urolithin-A ameliorated C. jejuni induced pro-inflammatory immune responses in the
intestinal tract of infected IL-10−/− mice.
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Figure 5. Intestinal pro-inflammatory mediator concentrations upon urolithin-A application to C. jejuni infected IL-10−/−
mice. Following C. jejuni strain 81-176 infection on days 0 and 1, microbiota depleted IL-10−/− mice were treated with
urolithin-A (URO, open circles) or placebo (PLC, closed circles) via the drinking water starting on d2 post infection. On d6
post infection, (A,B) IFN-γ secretion as well as (C) TNF-α, (D) MCP-1 and (E) nitric oxide concentrations were assessed in
ex vivo biopsies derived from the (A) colon and (B–E) ileum. Naive mice were used as negative controls (open diamonds).
Medians (black bars), significance levels (p values) calculated by the ANOVA test with Tukey post-correction or by the
Kruskal–Wallis test and Dunn’s post-correction and the total numbers of included animals (in parentheses) are given. Data
were pooled from three independent experiments.
2.5. Extra-Intestinal Pro-Inflammatory Mediators Upon Urolithin-A Treatment of C. jejuni
Infected IL-10−/− Mice
We next asked whether the immunomodulatory properties of exogenous urolithin-A
might also be observed in extra-intestinal tissues. On day 6 p.i., increased IFN-γ concentra-
tions were determined in lungs from placebo but not urolithin-A treated mice (p < 0.01;
Figure 6A). C. jejuni infection was further accompanied by elevated IFN-γ concentrations
in liver and kidney samples taken from mice of both cohorts (p < 0.01–0.001; Figure 6B,C),
but with a trend towards lower IFN-γ concentrations in urolithin-A versus placebo treated
mice (n.s. due to high standard deviations; Figure 6B,C).
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Figure 6. Extra-intestinal IFN-γ concentrations upon urolithin-A application to C. jejuni infected IL-10−/− mice. Following
C. jejuni strain 81-176 infection on days 0 and 1, microbiota depleted IL-10−/− mice were treated with urolithin-A (URO,
open circles) or placebo (PLC, closed circles) via the drinking water starting on d2 post infection. On d6 post infection,
extra-intestinal IFN-γ concentrations were measured in ex vivo biopsies derived from the (A) lungs, (B) liver and (C) kidneys.
Naive mice were used as negative controls (open diamonds). Medians (black bars), significance levels (p values) calculated
by the ANOVA test with Tukey post-correction or by the Kruskal–Wallis test and Dunn’s post-correction and the total
numbers of included animals (in parentheses) are given. Data were pooled from three independent experiments.
We further assessed systemic pro-inflammatory mediator secretion upon urolithin-A
application. On day 6 p.i., comparable IFN-γ and IL-6 concentrations were determined in
serum samples derived from mice of both treatment groups (n.s.; Figure 7A,C), but with
a trend towards lower IL-6 levels in urolithin-A versus placebo treated animals (n.s. due
to high standard deviations; Figure 7C). In mice from the placebo, but not the urolithin-A
cohort, however, increased MCP-1 serum concentrations were detected upon sacrifice
(p < 0.01 versus naive; Figure 7B). Hence, the immune response-dampening effects of
external urolithin-A could also be observed beyond the intestinal tract in extra-intestinal
compartments of C. jejuni infected IL-10−/− mice.
Figure 7. Systemic pro-inflammatory cytokine concentrations upon urolithin-A application to C. jejuni infected IL-10−/−
mice. Following C. jejuni strain 81-176 infection on days 0 and 1, microbiota depleted IL-10−/− mice were treated with
urolithin-A (URO, open circles) or placebo (PLC, closed circles) via the drinking water starting on d2 post infection. On d6
post infection, (A) IFN-γ, (B) MCP-1 and (C) IL-6 concentrations were measured in serum samples. Medians (black bars),
significance levels (p values) calculated by the ANOVA test with Tukey post-correction or by the Kruskal–Wallis test and
Dunn’s post-correction and the total numbers of included animals (in parentheses) are given. Data were pooled from three
independent experiments.
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3. Discussion
The work presented here is a first preclinical intervention study evaluating the disease-
alleviating efficacy of oral urolithin-A treatment in murine campylobacteriosis and reveals
that the anti-inflammatory properties of the ellagitannin derivative could ameliorate C. je-
juni infection locally in the intestinal tract and even beyond (i.e., in distinct extra-intestinal
tissues sites as well as systemically). Peroral application of urolithin-A versus placebo
to C. jejuni infected microbiota depleted IL-10−/− mice resulted in: (1) improved clin-
ical conditions observed as early as 24 hours following initiation of treatment; (2) less
distinct macroscopic intestinal sequelae as indicated by less colonic shrinkage; (3) less
pronounced microscopic inflammatory changes, as indicated by less colonic histopathology
and apoptosis; (4) lower abundance of macrophages, monocytes and T lymphocytes in the
colonic mucosa and lamina propria on day 6 p.i.; (5) reduced pro-inflammatory mediator
secretion in the intestinal tract and in extra-intestinal as well as systemic compartments.
In line with the absence of any clinical signs in more than one third of infected mice, the
significant reduction in wasting, fecal blood, and diarrhea in the treated versus control
animals demonstrates that the effects of urolithin-A concern all clinical aspects of C. jejuni
induced disease.
The fact that urolithin-A exerted all these beneficial properties without lowering the
C. jejuni loads in the colon is of importance given that promotion of C. jejuni resistance
against the drug is not relevant for successful treatment. The biological relevance of the
reduction in C. jejuni loads in the ilea of urolithin-A versus placebo treated IL-10−/− mice
is put in perspective by the low solubility of urolithin-A at concentrations above those
applied here. While the antimicrobial activity of urolithin-A against C. jejuni has not been
investigated so far, results from previous studies demonstrated that ellagitannins and
phlorotannins can inhibit C. jejuni growth in vitro [29,40,41].
Most importantly, urolithin-A treatment of acute murine campylobacteriosis resulted
in less pronounced macroscopic as well as microscopic inflammatory responses upon C. je-
juni infection. The better clinical outcome of the animals could be attributed to decreased
intestinal inflammation as indicated by lower histopathological scores in the treated versus
control animals. Significantly, reduced intestinal inflammatory cellular infiltrates indicate
that urolithin-A dampens the innate immune responses during the early phase of C. jejuni
infection. Given that the disease is characterized by infiltration of the intestinal tissues
by both innate and adaptive immune cell subsets, the alleviation of this histopathologi-
cal hallmark of human campylobacteriosis by urolithin-A treatment is essential for the
bench-to-bedside transfer of the obtained results. In line with the potent inhibition of
inflammatory infiltrates, the anti-inflammatory urolithin-A effects were further confirmed
by decreased numbers of macrophages and T lymphocytes in the intestines of treated as
compared to control animals. Furthermore, reduced numbers of apoptotic cells within
the colon of verum versus placebo treated mice point towards cell-protective effects of
urolithin-A in the intestinal tract during C. jejuni infection. In support, both urolithins
and the ellagitannins were shown to suppress apoptosis in inflammation [31,42,43]. Anti-
apoptotic effects of urolithin-A are also in agreement with the finding that urolithin-A
improved chemically induced colitis by activation of nuclear factor erythroid 2–related
factor 2 (Nrf 2) dependent intestinal epithelial barrier functions and aryl-hydrocarbon
receptor induced anti-inflammatory and anti-oxidative cellular pathways [44]. Similar
cell-protective mechanisms have been recently reported for urolithin derivatives [45], and
those intracellular pathways include protection against oxidative stress caused by ROS
and immune activators which are produced by innate immune cells in response to C. je-
juni-LOS and other bacterial factors triggering inflammation. The lowered nitric oxide
concentrations in the ileum of urolithin-A treated mice observed in this study are well in
line with the direct ROS scavenging functions of urolithin-A and its capacity to inhibit
ROS production by innate immune cells via blockage of MPO, LPO and inducible nitric
oxide synthase (iNOS) activities [31,34,38]. Furthermore, the inhibition of LPS mediated
activation of innate immune cells by urolithin-A has been well investigated in vitro, and
Pathogens 2021, 10, 7 10 of 16
this feature validated the analysis of the molecule as a potential candidate for novel phar-
maceutical interventions against campylobacteriosis in the present study [36,46,47]. The
multifactorial mechanisms by which urolithin-A exerts its anti-inflammatory activities
are completed by the inhibition of the central immune activator NFκB in innate immune
cells in vitro [35]. Given that C. jejuni induced pathologies include the activation of the
mammalian target of rapamycin (mTOR) and were ameliorated by rapamycin treatment in
IL-10−/− mice [48], it is noteworthy that urolithin-A was reported to downregulate mTOR
dependent pathways in cancer cells [49]. Taken together, these multi-faceted beneficial
effects of urolithin-A in ameliorating acute murine campylobacteriosis can be attributed
to a concerted action of cell-protective and anti-inflammatory mechanisms resulting in
dampened LPS/LOS induced inflammatory responses of the innate immune system upon
intestinal C. jejuni infection.
The anti-inflammatory effects of urolithin-A are further supported by the reduction in
soluble pro-inflammatory mediators including MCP-1, TNF-α and IFN-γ in the intestinal
tissues of treated versus control mice. This protects the animals from systemic inflammation,
as is further supported by the reduced extra-intestinal and even systemic pro-inflammatory
mediator secretions in the lungs, the kidneys and the liver as well as in the serum of
urolithin-A versus placebo-treated mice, respectively. In support, ellagitannins, coumarins
and urolithin-A reduced LPS-induced lung inflammation and osteoarthritis in respective
murine models of systemic inflammation [42,45,50]. However, systemic effects of urolithin-
A are controversially discussed mainly because upon resorption enzymatic modification of
urolithin-A leads to less active glucuronidated and sulfonated variants [29,36]. On the other
hand, continuous intake via drinking water was shown to elevate systemic urolithin-A
concentrations in mice and the resulting anti-oxidant capacity of murine sera contributed to
the healing of experimentally induced paw edema [51]. Furthermore, analysis of systemic
inflammation in LPS treated rats revealed that de-glucuronidation of urolithin is induced
at inflamed tissue sites [52].
The transfer of the here-obtained preclinical results to defined treatment measures
of human campylobacteriosis are supported by the fact that anti-inflammatory and gut
epithelial barrier strengthening functions of urolithins and ellagitannin precursors have
been confirmed in humans recently [42]. Furthermore, urolithin-A has been shown to exert
potent gut protective functions [43], and safety evaluation in humans and rats revealed the
complete absence of unwanted side effects [53]. Hence, patients suffering from campylobac-
teriosis may benefit from the ingestion of urolithin precursors in walnuts and pomegranate
juice, which are cheap and easily accessible. It is noteworthy that the ellagitannins present
in the food components also exhibit a wide range of biological activities including anti-
inflammatory, anti-thrombotic, anti-atherogenic, and anti-angiogenic properties in the
absence of unwanted side effects [29–31,33].
4. Materials and Methods
4.1. Ethical Statement
Animal welfare was monitored daily by assessment of clinical conditions. The experi-
ments in mice were carried out according to the European Guidelines for animal welfare
(2010/63/EU) and were approved by the commission for animal experiments located at the
“Landesamt für Gesundheit und Soziales” (LaGeSo, Berlin; registration number G0104/19,
approved on 15 July 2019).
4.2. Microbiota Depleted IL-10−/− Mice
All mice were bred in the Forschungsinstitute für Experimentelle Medizin, Charité—
University Medicine Berlin (Germany). In the age of six weeks IL-10−/− mice in the
C57BL/6j background were kept in cages with filter tops in a semi-barrier setting un-
der standard conditions (55 ± 15% air humidity) at room temperature (22–24 ◦C) with
a 12-hour light and a 12-hour dark cycle. The animals had free access to autoclaved wa-
ter and standard chow consisting of food pellets (ssniff R/M-H, V1534-300, Sniff, Soest,
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Germany). By the age of 7 weeks, female and male mice were transferred to sterile cages
(maximum of 4 animals per cage) and treated with an antibiotic cocktail consisting of ampi-
cillin plus sulbactam (1 g/L; Dr. Friedrich Eberth Arzneimittel, Ursensollen, Germany),
vancomycin (500 mg/L; Hikma Pharmaceuticals, London, UK), ciprofloxacin (200 mg/L;
Fresenius Kabi, Bad Homburg, Germany), imipenem (250 mg/L; Fresenius Kabi, Bad
Homburg, Germany) and metronidazole (1 g/L; B. Braun, Melsungen, Germany) for eight
weeks (via the drinking water, ad libitum). This broad-spectrum antibiotic treatment led
to a virtual depletion of the commensal intestinal microbiota, as shown earlier [39,54].
Microbiota-depleted mice received autoclaved food and tap water. To minimize the risk
of contaminations, the animals were continuously kept and handled under strict aseptic
conditions. Three days prior to C. jejuni infection, the antibiotic cocktail was replaced by
autoclaved tap water to assure washout of the antibiotics.
4.3. Campylobacter jejuni Infection
Age- and sex-matched secondary abiotic IL-10−/− mice (4-month-old litter mates)
were infected perorally with 109 CFU of the C. jejuni strain 81-176 on days 0 and 1 by oral
gavage. The C. jejuni bacteria originating from a standardized frozen stock were first grown
on selective Karmali agar plates and on columbia agar with 5% sheep blood. Both solid
growth media were purchased from Oxoid (Wesel, Germany).
4.4. Urolithin-A Treatment
Treatment of mice with urolithin-A (Sigma-Aldrich, Munich, Germany) in drinking
water was performed with a daily dose of 0.114 mg urolithin-A per kg body weight per
day. This was achieved by dissolving the compound in autoclaved tap water (ad libitum)
to a final concentration of 22.8 mg/L. Mice received access to the urolithin-A solution from
two days after the first C. jejuni infection. The placebo control mice received autoclaved tap
water instead.
4.5. Gastrointestinal C. jejuni Loads and Bacterial Translocation
C. jejuni concentrations were determined in luminal samples taken from the stomach,
duodenum, ileum, colon and in feces over time p.i. as well as in homogenates of ex
vivo biopsies taken from mesenteric lymph nodes (MLN), spleens, livers, kidneys and
cardiac blood upon necropsy by culture, as described previously [12,55]. The intraluminal
gastrointestinal samples and respective ex vivo biopsies were homogenized in sterile
phosphate buffered saline (PBS; Thermo Fisher Scientific, Waltham, MA, USA), and serial
dilutions were plated onto columbia agar (with 5% sheep blood) and Karmali agar (both
from Oxoid, Wesel, Germany). Bacterial growth was monitored after incubation of solid
media in a microaerophilic atmosphere for at least 48 hours (37 ◦C). Cardiac blood (0.2 mL)
was immediately streaked onto Karmali agar plates. The detection limit of viable C. jejuni
was 100 CFU per gram analyzed sample.
4.6. Clinical Outcome
The clinical outcome of campylobacteriosis in mice was assessed immediately before
and after infection once daily by using a standardized cumulative clinical score (maximum
12 points) as described earlier [22]. The clinical score addressed the clinical aspect/wasting
(0: normal; 1: ruffled fur; 2: less locomotion; 3: isolation; 4: severely compromised loco-
motion, pre-final aspect) and the abundance of blood in feces (0: no blood; 2: microscopic
detection of blood by the Guajac method using Haemoccult, Beckman Coulter/PCD,
Krefeld, Germany; 4: macroscopic blood visible) as well as the stool consistency (0: formed
feces; 2: pasty feces; 4: liquid feces).
4.7. Sampling Procedures
On day 6 p.i., mice were sacrificed by CO2 asphyxiation and colonic lengths were
measured with a ruler. From each animal cardiac blood, ex vivo biopsies of lungs, livers,
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kidneys, MLN, ileum and colon as well as luminal samples from stomach, duodenum,
ileum, and colon were derived under aseptic conditions.
4.8. Histopathology
Histopathological analyses were performed in colonic ex vivo biopsies (immediately
fixed in 5% formalin, embedded in paraffin, and stained with hematoxylin and eosin) as
reported previously [56]. Briefly, gross histopathological changes assessed microscopically
in 100 times magnified tissue sections of 5 µm thickness were scored by an independent
investigator using an established histopathological scoring system: Score 1: minimal in-
flammatory cell infiltrates in the mucosa with intact epithelium. Score 2: mild inflammatory
cell infiltrates in the mucosa and submucosa with mild hyperplasia and mild goblet cell
loss. Score 3: moderate inflammatory cell infiltrates in the mucosa with moderate goblet
cell loss. Score 4: marked inflammatory cell infiltration into in the mucosa and submucosa
with marked goblet cell loss, multiple crypt abscesses and crypt loss.
4.9. In Situ Immunohistochemistry
Quantitative in situ immunohistochemical analyses were performed by counting
positively stained cells by blinded independent investigators microscopically in at least
six high power fields (HPF, 0.287 mm2, 400 × magnification) of tissue sections (see above)
of intestinal ex vivo biopsies as recently reported [20,57]. In brief, detection of apoptotic
epithelial cells, macrophages and monocytes, T lymphocytes, regulatory T cells and B
lymphocytes, 5 µm thin colonic paraffin sections were stained with primary antibodies
directed against cleaved caspase3 (Asp175, Cell Signaling, Beverly, MA, USA, 1:200), F4/80
(no. 14-4801, clone BM8, eBioscience, San Diego, CA, USA, 1:50), CD3 (no. N1580, Dako,
1:10), FOXP3 (clone FJK-165, no. 14-5773, eBioscience, 1:100) and B220 (no. 14-0452-81,
eBioscience; 1:200), respectively.
4.10. Measurement of Pro-Inflammatory Mediators
Pro-inflammatory mediator and nitric oxide secretion in serum samples and in ex vivo
biopsies were measured with the Mouse Inflammation Cytometric Bead Assay (CBA; BD
Biosciences, Heidelberg, Germany) in a BD FACSCanto II flow cytometer (BD Biosciences,
Heidelberg, Germany) and by the Griess reaction [39,58], respectively. Measurements were
undertaken in supernatants of ex vivo biopsies that had been incubated in 24-flat-bottom
well culture plates (Thermo Fisher Scientific, Waltham, MA, USA) containing 500 µL serum-
free RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) after incubation at
37 ◦C for 18 hours. Respective culture supernatants and serum samples were tested for
IFN-γ, TNF-α, MCP-1 and IL-6. Briefly, the biopsies obtained from the colon and ileum
were longitudinally cut in strips of approximately 1 cm2 and washed in PBS (Thermo Fisher
Scientific, Waltham, MA, USA). The extra-intestinal ex vivo biopsies were taken from one
lung, the liver (approximately 1 cm3) and one-half of a kidney (after longitudinal cut). The
biopsies were supplemented with penicillin (100 µg/mL) and streptomycin (100 µg/mL;
Biochrom, Berlin, Germany).
4.11. Statistical Analyses
The medians and significance levels were calculated by using GraphPad Prism v8,
USA. For pairwise comparisons of normally and not normally distributed data, the Stu-
dent’s t test and the Mann–Whitney test were applied, respectively. Furthermore, for
multiple comparisons we used the one-sided ANOVA with Tukey post-correction (for nor-
mally distributed data) and the Kruskal–Wallis test with Dunn’s post-correction (for not
normally distributed data). After definite outliers were removed by identification with the
Grubb’s test (α = 0.001), two-sided probability (p) values ≤ 0.05 were considered significant.
We used pooled data from three independent experiments for all the analyses.
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5. Conclusions
In conclusion, synthetic urolithin-A has a promising potency as alternative, antibiotic-
independent treatment option to tackle acute campylobacteriosis by dampening the innate
immune responses upon C. jejuni infection of the intestinal tract. The molecule can easily be
applied via drinking water and is active in the intestines at low concentrations, even in the
µM range. Besides the major modes of actions of oral synthetic urolithin-A application, our
results further underline the important role of LOS mediated innate immune activation in
C. jejuni induced enteritis and the feasibility of the here applied acute microbiota-depleted
IL-10−/− mouse model for the preclinical evaluation of future treatment options in acute
campylobacteriosis.
Supplementary Materials: The following are available online at https://www.mdpi.com/2076-081
7/10/1/7/s1, Figure S1: Kinetic survey of fecal pathogen loads following urolithin-A treatment of
C. jejuni infected IL-10−/− mice. Figure S2: Kinetic survey of the clinical outcome of C. jejuni infected
IL-10−/− mice upon urolithin-A treatment.
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